SENSEX 77414.92 ▼ (0.25%)
BSE BANKEX 59542.38 ▲ (0.36%)

BIOCON

BSE: 532523 29 Jun 2025
Healthcare
₹ 352.1
Biocon Ltd. specializes in Pharmaceuticals within the Healthcare sector.

BIOCON - Share Price & Details

Market Cap
₹47,382
High /Low
405.0 / 291.0
Stock P/E
49.3
Book Value
₹180.0
Dividend Yield
0.14
ROCE
6.13
ROE
₹4.64
Face Value
5.0
PEG Ratio
7.47
EVEBITDA
₹14.1
Debt
18,362
CMP / FCF
49.1
Debt to equity
₹0.85
NP Ann
1,429
High price all time
488.0
Piotroski score
₹6.0
Graham Number
185.0
No. Eq. Shares
134.0
Net CF
₹1,973
Net profit
1,429
Price to book value
1.97
Interest Coverage
₹2.99
Low price all time
14.2
Industry PE
32.7
Reserves
₹21,044
Free Cash Flow
₹1,718

Price Chart


Volume Chart


Peer Comparison

Stock Total Income Net Profit Net Sales EPS Market Cap (in Cr) P/E
LOOKS HEALTH SERVICES LIMITEDNANANANA5.11256.0
Triochem Products Ltd.,NANANANA0
BIOCON LTD.44539.04594.044170.02.8747,38249.3
Narayana Hrudayalaya LimitedNANANANA4625158.1
Laurus Labs Limited17221.72519.016500.14.6737845118.0

Peer Comparison Chart


About BIOCON

Biocon Ltd., with Security Code 532523, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.


Latest News

Stock To Buy: Biocon, LIC, Tech Mahindra, Valor Estate, Voltas

(12 Jun 2025)
Analysts chose Biocon Ltd., Life Insurance Corp of India, Tech Mahindra Ltd., Valor Estate Ltd., and Voltas Ltd. for Thursday's trading...
Read more →

Biocon Ltd soars 3.52%, Gains for third straight session

(11 Jun 2025)
Biocon Ltd is quoting at Rs 353.2, up 3.52% on the day as on 12:49 IST on the NSE. The stock is up 4.22% in last one year as compared to a...
Read more →

Biocon's Stock Rebounds Amidst Broader Market Optimism and Small-Cap Gains

(10 Jun 2025)
Biocon Ltd. experienced a notable performance on June 9, 2025, reversing a two-day decline and outperforming its sector.
Read more →

Biocon Gains 1% After India Nod for Diabetes Drug Liraglutide

(05 Jun 2025)
Biocon Ltd rose 1% to Rs 340 after receiving regulatory approval for its Liraglutide drug substance. Discover more now.
Read more →

Biocon gets approval for diabetes drug Liraglutide in India

(05 Jun 2025)
The approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus.
Read more →

Biocon shares in focus after CDSCO nod for diabetes drug Liraglutide

(05 Jun 2025)
Biocon shares are in focus as the company has received regulatory approval from the Central Drugs Standard Control Organisation for its...
Read more →